Cleerly, Inc

Cleerly is an AI-driven software platform that enhances coronary CT angiography (CCTA) analysis for comprehensive coronary artery disease (CAD) assessment. The platform delivers quantitative, clinically actionable insights through automated 3D modeling of coronary arteries, plaque detection and characterization, stenosis measurement, and ischemia likelihood determination. Cleerly's core offerings include: AI-powered CAD analysis with 3D arterial reconstruction; plaque phenotyping (soft, fibrous, calcified); stenosis quantification in 2D and 3D; ischemia assessment via the proprietary Cleerly ISCHEMIA algorithm; and serial scan comparison (Cleerly COMPARE) for longitudinal CAD tracking. The platform integrates with PowerScribe for streamlined reporting workflows. Clinical validation includes the prospective CREDENCE trial (868 invasive FFR measurements) demonstrating superior diagnostic accuracy versus FFRCT and stress testing, and post-hoc PACIFIC study analysis showing Cleerly ISCHEMIA as the only non-invasive test prognostic of major adverse cardiac events. The solution targets cardiologists, interventional radiologists, and cardiac imaging centers seeking to reduce unnecessary invasive procedures and improve diagnostic confidence. The company supports commercial insurance reimbursement and provides web-based access to the platform. Designed for hospital and outpatient cardiac imaging workflows.